Abstract：
Over the past decades, accumulating evidence suggests that the gut microbiome exerts a key role in Alzheimer\'s disease (AD). The Alzheimer\'s Association Workgroup is updating the diagnostic criteria for AD, which changed the profiles and categorization of biomarkers from \"AT(N)\" to \"ATNIVS.\" Previously, most of studies focus on the correlation between the gut microbiome and amyloid beta deposition (\"A\"), the initial AD pathological feature triggering the \"downstream\" tauopathy and neurodegeneration. However, limited research investigated the interactions between the gut microbiome and other AD pathogenesis (\"TNIVS\"). In this review, we summarize current findings of the gut microbial characteristics in the whole spectrum of AD. Then, we describe the association of the gut microbiome with updated biomarker categories of AD pathogenesis. In addition, we outline the gut microbiome-related therapeutic strategies for AD. Finally, we discuss current key issues of the gut microbiome research in the AD field and future research directions. HIGHLIGHTS: The new revised criteria for Alzheimer\'s disease (AD) proposed by the Alzheimer\'s Association Workgroup have updated the profiles and categorization of biomarkers from \"AT(N)\" to \"ATNIVS.\" The associations of the gut microbiome with updated biomarker categories of AD pathogenesis are described. Current findings of the gut microbial characteristics in the whole spectrum of AD are summarized. Therapeutic strategies for AD based on the gut microbiome are proposed.
摘要：
在过去的几十年里，越来越多的证据表明，肠道微生物群在阿尔茨海默病（AD）中起着关键作用。阿尔茨海默氏症协会工作组正在更新AD的诊断标准，将生物标志物的概况和分类从“AT（N）”更改为“ATNIVS”。\"以前,大多数研究集中在肠道微生物组和淀粉样β沉积之间的相关性(“A”)，最初的AD病理特征触发了“下游”tau蛋白病和神经变性。然而,有限的研究调查了肠道微生物组和其他AD发病机制(“TNIVS”)之间的相互作用。在这次审查中,我们总结了目前在AD的整个光谱中肠道微生物特征的发现。然后，我们描述了肠道微生物组与AD发病机制的最新生物标志物类别之间的关联.此外,我们概述了AD的肠道微生物组相关治疗策略。最后,我们讨论了当前AD领域肠道微生物组研究的关键问题和未来的研究方向。重点：阿尔茨海默病协会工作组提出的新修订的阿尔茨海默病（AD）标准已将生物标志物的概况和分类从“AT（N）”更新为“ATNIVS”。“描述了肠道微生物组与AD发病机制的最新生物标志物类别的关联。总结了目前在AD全谱中肠道微生物特征的发现。提出了基于肠道微生物组的AD治疗策略。
